Eloralintide vs Thymagen
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideImmune Support
Thymagen- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- Half-Life
- ~7 days (estimated, long-acting design)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 10 mg per day
- Frequency
- Once weekly
- Daily for 10–30 days
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Stacks With
- —
- —